We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GLOBETECH PUBLISHING LLC

Download Mobile App




Breakthrough Ultrasound Technology Offers Disruptive, Non-Invasive Treatment Option for Aortic Stenosis

By MedImaging International staff writers
Posted on 17 Mar 2022
Print article
Image: Patient affected by severe symptomatic aortic stenosis treated with Valvosoft (Photo courtesy of Amphia Ziekenhuis)
Image: Patient affected by severe symptomatic aortic stenosis treated with Valvosoft (Photo courtesy of Amphia Ziekenhuis)

Aortic stenosis is a degenerative and potentially life-threatening condition, caused by calcium build-up which prevents the aortic valve from fully opening, leading to heart failure. The only current medical response is to replace the aortic valve with open heart surgery, or with a minimally invasive percutaneous valve (TAVI). Now, a new non-invasive treatment combining therapeutic ultrasound, robotics and ultrasound imaging brings great hope for patients with aortic stenosis and for their families.

Cardiawave SA (Paris, France) has developed VALVOSOFT, a revolutionary non-invasive medical device to treat aortic stenosis, the most prevalent heart valve disease in adults. VALVOSOFT is a breakthrough technology that allows for the remote application of an extremely precise and focused therapeutic ultrasound beam to restore valve function in patients with aortic stenosis. This intense beam decreases the stiffness of the aortic valve and improves its functional opening to allow sufficient oxygenated blood to reach the brain and the rest of the body.

Cardiawave has also announced the success of its First-In-Human I (FIH I) clinical trial to assess the safety, and operating system of the first generation of VALVOSOFT as well as the clinical effects of softening calcific aortic valve tissues with a beating heart. 30 patients (average age 84 years, with nine patients aged over 90 years) have been successfully treated. VALVOSOFT provided a sustained repair to the aortic vavlve for up to 12 months post treatment. The study has proven the safety and efficacy, as well as the ease of the procedure with a 60 minute non-invasive outpatient treatment. Following the successful VALVOSOFT treatment, two patients were able to have TAVI valve replacement.

VALVOSOFT non-invasive treatment offers the possibility of an efficient outpatient treatment for fragile patients, for whom valve replacement is too risky. In the longer term, treating patients with less severe stenosis would be a major step forward. A second feasibility and safety FIH II study is underway with 10 further patients. This includes brain MRI evaluation both before and after treatment to assess the risk of a stroke. Four patients were safely treated by the end of December 2021. None of the MRIs detected an abnormality. Six further patients will be treated during H1 2022.

“The positive results of the safety and feasibility clinical studies we observed in our First In Human trial are extremely encouraging. We have shown that VALVOSOFT can treat patients who are exceedingly fragile and sick for whom no medical solution exists today. This represents a new treatment solution for aortic stenosis, over and above aortic valve replacement from which only a small minority of patients can benefit. Cardiawave’s VALVOSOFT has the potential to become a standard new treatment for this deadly disease," said Benjamin Bertrand, CEO of Cardiawave. "We are currently working on receiving the necessary authorizations in Europe for further clinical trials over the next few months. I am confident that these will once again confirm the therapeutic benefits of VALVOSOFT.”

Related Links:
Cardiawave SA 

Gold Member
Solid State Kv/Dose Multi-Sensor
AGMS-DM+
New
Ultrasound Doppler System
Doppler BT-200
New
DR Flat Panel Detector
1500L
MRI System
uMR 588

Print article

Channels

Radiography

view channel
:	Image: The AI model could be a valuable adjunct to human radiologists in breast cancer diagnoses and risk prediction (Photo courtesy of 123RF)

AI Model Predicts 5-Year Breast Cancer Risk from Mammograms

Approximately 13% of U.S. women, or one in every eight, are predicted to develop invasive breast cancer over their lifetime, with 1 in 39 women (3%) succumbing to the illness, according to the American... Read more

Nuclear Medicine

view channel
Image: The AI system uses scintigraphy imaging for early diagnosis of cardiac amyloidosis (Photo courtesy of 123RF)

AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging

Cardiac amyloidosis, a condition characterized by the buildup of abnormal protein deposits (amyloids) in the heart muscle, severely affects heart function and can lead to heart failure or death without... Read more

General/Advanced Imaging

view channel
Image: The CIARTIC Move self-driving mobile C-arm has received FDA clearance (Photo courtesy of Siemens)

Self-Driving Mobile C-Arm Reduces Imaging Time during Surgery

Intraoperative imaging faces significant challenges due to staff shortages and the high demands placed on surgical teams in the operating room (OR). A common challenge during many OR procedures is the... Read more

Imaging IT

view channel
Image: The new Medical Imaging Suite makes healthcare imaging data more accessible, interoperable and useful (Photo courtesy of Google Cloud)

New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible

Medical imaging is a critical tool used to diagnose patients, and there are billions of medical images scanned globally each year. Imaging data accounts for about 90% of all healthcare data1 and, until... Read more

Industry News

view channel
Image: Samsung Medison CEO Mr. Yongkwan Kim and Bracco Imaging CEO Dr. Fulvio Renoldi Bracco endorsed a MoU agreement (Photo courtesy of Bracco Group)

Samsung and Bracco Enter Into New Diagnostic Ultrasound Technology Agreement

Samsung Medison (Seoul, South Korea) and Bracco Imaging (Milan, Italy) have entered into a Memorandum of Understanding (MoU) agreement to pioneer a new area for diagnostic ultrasound devices and contrast agents.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.